Plain-English translation of NCT06079333 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two targeted medications called dabrafenib and trametinib in people with a rare and aggressive form of thyroid cancer called anaplastic thyroid cancer that has a specific genetic change (BRAF mutation). The idea is to give these medications before surgery to shrink the tumor and make it easier to remove completely, and then continue the medication afterward to prevent the cancer from coming back.
Anaplastic thyroid cancer is extremely serious and very difficult to treat. Surgery is often the best chance for survival, but most patients cannot have their tumors completely removed. The new approach in this trial is to use this medication first to shrink the tumor and get rid of any cancer cells that may have spread, which researchers hope will make surgery more successful and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You will take the targeted medications by mouth for 6 weeks, then have imaging and tests to see if your tumor can be safely removed. If it can be removed, you'll have surgery and then continue taking the medications for up to a year total. If your tumor cannot be removed after the first 6 weeks, you'll continue the medications for another 6 weeks and be reassessed. Throughout the study, you'll have regular clinic visits, blood tests, and imaging scans to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Netherlands